Hi POS
Understood, but I anticipate the inclusion criteria are such to demonstrate a clear proof of concept/cause and effect within a relatively short time frame.
I don't see any reason why the drug would be limited to up to 6 hrs post TBI in a post trial clinical setting, assuming it makes through to market. It's obviously fine as a regular dosing regimen (given retts results), I still expect there will be clinical application beyond the trial inclusion criteria, particularly for increased tbi severity.
The Case for Yes, page-21
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.27 |
Change
0.920(6.41%) |
Mkt cap ! $1.951B | |||
| Open | High | Low | Value | Volume |
| $14.35 | $15.27 | $14.35 | $8.720M | 579.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $15.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.27 | 3638 | 4 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |